NCT06505265View on ClinicalTrials.gov

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions

Healthy Participants

Interventions

DRUG

Povorcitinib

Oral; Tablet

Trial Locations (1)

68502

Celerion, Inc, Lincoln

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY